Abstract:Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these medicines are outdated, have severe side effects, and often become less efficacious over time, necessitating the need for insulin therapy. G protein–coupled receptors (GPCRs) regulate many physiologic processes, including blood glucose levels. In pancreatic β cells, GPCRs regulate β -cell growth, apoptosis, and insulin secretion, which are all critical in maintaining sufficient β -cell mass and insulin output to ensure euglycemia. In recent years, new insights into the signaling of incretin receptors and other GPCRs have underscored the potential of these receptors as desirable targets in the treatment of diabetes. The signaling of these receptors is modulated by GPCR kinases (GRKs) that phosphorylate agonist-activated GPCRs, marking the receptor for arrestin binding and internalization. Interestingly, genome-wide association studies using diabetic patient cohorts link the GRKs and arrestins with T2D. Moreover, recent reports show that GRKs and arrestins expressed in the β cell serve a critical role in the regulation of β -cell function, including β -cell growth and insulin secretion in both GPCR-dependent and -independent pathways. In this review, we describe recent insights into GPCR signaling and the importance of GRK function in modulating β -cell physiology. Significance Statement Pancreatic β cells contain a diverse array of G protein–coupled receptors (GPCRs) that have been shown to improve β -cell function and survival, yet only a handful have been successfully targeted in the treatment of diabetes. This review discusses recent advances in our understanding of β -cell GPCR pharmacology and regulation by GPCR kinases while also highlighting the necessity of investigating islet-enriched GPCRs that have largely been unexplored to unveil novel treatment strategies.

Biomedical aspects of beta-glucan on glucose metabolism and its role on primary gene PIK3R1

PI3K/Akt Signaling Axis in Regulation of Glucose Homeostasis

Glycogen synthase kinase-3: A potential target for diabetes

Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality.

Current Insight on the Role of Glucokinase and Glucokinase Regulatory Protein in Diabetes

Pi 3-Kinase and Its Up- and Down-Stream Modulators As Potential Targets for the Treatment of Type II Diabetes.

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.

PI3K Signaling: a Crossroads of Metabolic Regulation

The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes

Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis

Metabolites of traditional Chinese medicine targeting PI3K/AKT signaling pathway for hypoglycemic effect in type 2 diabetes

The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity

Exploration of Potent Human α ‐Glucosidase Inhibitors Using In Silico Approaches: Molecular Docking, DFT, Molecular Dynamics Simulations, and MMPBSA

Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach Towards the Treatment of Type Two Diabetes

Epicatechin and β-Glucan from Whole Highland Barley Grain Synergistic Benefit on Attenuating Hyperglycemia via Improving Hepatic Glucose Metabolism in Diabetic C57BL/6J Mice

A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

The role of glucose-6-phosphatase activity in glucose homeostasis and its potential for diabetes therapy

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase

Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future